GM1 ganglioside: In vivo and in vitro trophic actions on central neurotransmitter systems

Journal of Neurochemistry

Volumn 70, Issue 4, 1998, Pages 1335-1345

  Hadjiconstantinou, Maria ^a   Neff, Norton H ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Acetylcholine; Aging; Anim al models; Dopamine; GM1 ganglioside; Neuronal injury; Neuroprotection; Neurorestoration; Primary neuronal cultures; Serotonin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AZIRIDINE DERIVATIVE; GANGLIOSIDE GM1; IBOTENIC ACID; MUSTARD GAS DERIVATIVE; NERVE GROWTH FACTOR; NEUROTOXIN; OXIDOPAMINE;

AGING; ANIMAL EXPERIMENT; CHOLINERGIC SYSTEM; DOPAMINERGIC SYSTEM; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NERVE CELL LESION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SHORT SURVEY;

EID: 0031930026     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.70041335.x     Document Type: Short Survey

References (119)

1. Agnati L. F., Fuxe K., Calza L., Benfenati F., Cavicchioli L., Toffano G., and Goldstein M. (1983a) Gangliosides increase the survival of lesioned nigral dopamine neurons and favour the recovery of dopaminergic synaptic function in striatum of rats by collateral sprouting. Acta Physiol. Scand. 119, 347-363.
2. Agnati L. F., Fuxe K., Benfenati F., Battistini N., Zini I., and Toffano G. (1983b) Chronic ganglioside treatment counteracts the biochemical signs of dopamine receptor supersensitivity induced by chronic haloperidol treatment. Neurosci. Lett. 40, 293-297.
3. Agnati L. F., Fuxe K., Calza L., Goldstein M., Toffano G., Giardino L., and Zoli M. (1984) Further studies on the effects of the GM1 ganglioside on the degenerative and regenerative features of mesostriatal dopamine neurons. Acta Physiol. Scand. Suppl. 532, 37-44.
4. Andreassen O. A. and Jorgensen H. A. (1994) GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats. Psychopharmacology (Berl.) 116, 517-522.
5. Baker H. J. and Jope R. S. (1985) Increased metabolism of acetylcholine in brain of cats with GM1 gangliosidosis. Brain Res. 343, 363-365.
6. Cannella M. S., Oderfeld-Nowak B., Gradkowska M., Skup M., Garofalo L., Cuello A. C., and Ledeen R. W. (1990) Derivatives of ganglioside GM1 as neuronotrophic agents: comparison of in vivo and in vitro effects. Brain Res. 513, 286-294.
7. Casamenti F., Bracco L., Bartolini L., and Pepeu G. (1985) Effects of ganglioside treatment in rats with a lesion of the cholinergic forebrain nuclei. Brain Res. 338, 45-52.
8. Casamenti F., Di Patre P. L., Milan F., Petrelli L., and Pepeu G. (1989) Effects of nerve growth factor and GM1 ganglioside on the number and size of cholinergic neurons in rats with unilateral lesion of nucleus basalis. Neurosci. Lett. 103, 87-91.
9. Casamenti F., Scali C., Giovannelli L., Faussone-Pellegrini M. S., and Pepeu G. (1994) Effects of nerve growth factor and GM1 ganglioside on the recovery of cholinergic neurons after a lesion of the nucleus basalis in aging rats. J. Neural Transm. 7, 177-193.
10. Contestabile A., Virgili M., Migani P., and Barnabei O. (1990) Effects of short-and long-term ganglioside treatment on the recovery of neurochemical markers in the ibotenic acid-lesioned rat striatum. J. Neurosci. Res. 26, 483-487.
11. Cuello A. C. (1990) Glycosphingolipids that can regulate nerve growth and repair. Adv. Pharmacol 21, 1-50.
12. Cuello A. C., Stephens P. H., Tagari P. C., Sofroniew M. V., and Pearson R. C. (1986) Retrograde changes in the nucleus basalis of the rat, caused by cortical damage, are prevented by exogenous ganglioside GM1. Brain Res. 376, 373-377.
13. Cuello A. C., Garofalo L., Konigsberg R. L., and Maysinger D. (1989) Gangliosides potentiate in vivo and in vitro effects of nerve growth factor on central cholinergic neurons. Proc. Natl. Acad. Sci. USA 86, 2056-2060.
14. +. J. Neurosci. 13, 3104-3111.
15. +: the consequences of treatment with GM1 ganglioside. Brain Res. 742, 260-264.
16. Date I., Felten S. Y., and Felten D. L. (1989) Exogenous GM1 ganglioside induces partial recovery of the nigrostriatal dopaminergic system in MPTP-treated young mice but not in aging mice. Neurosci. Lett. 106, 282-286.
17. Date I., Notter M. F., Felten S. Y., and Felten D. L. (1991) Stereotaxic injection of GD1a ganglioside induces limited recovery of striatal dopaminergic system in MPTP-treated aging mice. J. Neurosci. Res. 28, 525-530.
18. Derrington E. A. and Whittaker V. P. (1993) The cholinergic marker Chol-1 is selectively localized in nerve terminals. Neuroreport 4, 317-319.
19. Derrington E. A., Kelic S., and Whittaker V. P. (1993) A novel cholinergic-specific antigen (Chol-2) in mammalian brain. Brain Res. 620, 16-23.
20. Di Patre P. L., Casamenti F., Cenni A., and Pepeu G. (1989) Interaction between nerve growth factor and GM1 monosialoganglioside in preventing cortical choline acetyltransferase and high affinity choline uptake decrease after lesion of the nucleus basalis. Brain Res. 480, 219-224.
21. Duchemin A.-M., Neff N. H., and Hadjiconstantinou M. (1997) Induction of Trk phosphorylation by GM1 ganglioside in rat brain. (Abstr.) J. Neurochem. 69 (Suppl.), S33.
22. Elliot P. J., Garofalo L., and Cuello A. C. (1989a) Responsiveness to dopaminergic agonists after devascularizing lesions of the cortex. Neuropharmacology 28, 397-400.
23. Elliott P. J., Garofalo L., and Cuello A. C. (1989b) Limited neocortical devascularizing lesions causing deficits in memory retention and choline acetyltransferase activity - effects of monosialoganglioside GM1. Neuroscience 31, 63-76.
24. Emborg M. E. and Colombo J. A. (1994) Long-term MPTP-treated monkeys are resistant to GM1 systemic therapy. Mol. Chem. Neuropathol. 21, 75-82.
25. Emerich D. F. and Walsh T. J. (1990) Ganglioside AGF2 promotes task-specific recovery and attenuates the cholinergic hypofunction induced by AF64A. Brain Res. 527, 299-307.
26. Fadda E., Negro A., Facci L., and Skaper S. D. (1993) Ganglioside GM1 cooperates with brain-derived neurotrophic factor to protect dopaminergic neurons from 6-hydroxydopamine-induced degeneration. Neurosci. Lett. 159, 147-150.
27. Farooqui T., Franklin T., Pearl D. K., and Yates A. L. (1997) Ganglioside GM1 enhances induction by nerve growth factor of a putative dimer of TrkA. J. Neurochem. 68, 2348-2355.
28. Ferrari G., Anderson B. L., Stephens R. M., Kaplan D. R., and Greene L. A. (1995) Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors. J. Biol. Chem. 270, 3074-3080.
29. Ferretti P. and Borroni E. (1986) Putative cholinergic-specific gangliosides in guinea pig forebrain. J. Neurochem. 46, 1888-1894.
30. Florian A., Casamenti F., and Pepeu G. (1987) Recovery of cortical acetylcholine output after ganglioside treatment in rats with lesion of the nucleus basalis. Neurosci. Lett. 75, 313-316.
31. Fong T. G., Neff N. H., and Hadjiconstantinou M. (1995a) Systemic administration of GM1 ganglioside increases choline acetyltransferase activity in the brain of aged rats. Exp. Neurol. 132, 157-161.
32. Fong T. G., Vogelsberg V., Neff N. H., and Hadjiconstantinou M. (1995b) GM1 and NGF synergism on choline acetyltransferase and choline uptake in aged brain. Neurobiol. Aging 16, 917-923.
33. Fong T. G., Neff N. H., and Hadjiconstantinou M. (1997a) GM1 ganglioside improves spatial learning and memory in aged rats. Behav. Brain Res. 85, 203-211.
34. Fong T. G., Vogelsberg V., Neff N. H., and Hadjiconstantinou M. (1997b) Restorative effects of systemic GM1 ganglioside administration on the aged brain. (Abstr.) J. Neurochem. 69 (Suppl.), S246.
35. Fusco M., Dona M., Tessari F., Hallman H., Jonsson G., and Gorio A. (1986) GM1 ganglioside counteracts selective neurotoxin-induced lesion of developing serotonin neurons in rat spinal cord J. Neurosci. Res. 15, 467-479.
36. Fusco M., Figliomeni B., Gorio A., and Vantini G. (1988) Postnatal development of bulbospinal serotonergic systems. Effects of GM1 ganglioside following neonatal 5,7-dihydroxytryptamine treatment. Neurochem. Int. 13, 251-259.
37. Garofalo L. and Cuello A. C. (1994) Nerve growth factor and the monosialoganglioside GM1: analogous and different in vivo effects on biochemical, morphological, and behavioral parameters of adult cortically lesioned rats. Exp. Neurol. 125, 195-217.
38. Garofalo L. and Cuello A. C. (1995) Pharmacological characterization of nerve growth factor and/or monosialoganglioside GM1 effects on cholinergic markers in the adult lesioned brain. J. Pharmacol. Exp. Ther. 272, 527-545.
39. Garofalo L., Ribeiro-da-Silva A., and Cuello A. C. (1993) Potentiation of nerve growth factor-induced alterations in cholinergic fiber length and presynaptic terminal size in cortex of lesioned rats by the monosialoganglioside GM1. Neuroscience 57, 21-40.
40. Ghidoni R., Fiorilli A., Trinchera M., Venerando B., Chigorno V., and Tettamanti G. (1989) Uptake, cell penetration and metabolic processing of exogenously administered GM1 ganglioside in rat brain. Neurochem. Int. 15, 455-465.
41. Gradkowska M., Skup M., Kiedrowski L., Calzolari S., and Oderfeld-Nowak B. (1986) The effect of GM1 ganglioside on cholinergic and serotoninergic systems in the rat hippocampus following partial denervation is dependent on the degree of fiber degeneration. Brain Res. 375, 417-422.
42. Green A. R., De Souza R. J., Williams J. L., Murray T. K., and Cross A. J. (1992) The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlormethiazole. Neuropharmacology 31, 315-321.
43. Gupta M., Schwarz J., Chen X. L., and Roisen F. J. (1990) Gangliosides prevent MPTP toxicity in mice: an immunocytochemical study. Brain Res. 527, 330-334.
44. Hadjiconstantinou M. and Neff N. H. (1986) Treatment with GM1 ganglioside increases rat spinal cord indole content. Brain Res. 366, 343-345.
45. Hadjiconstantinou M. and Neff N. H. (1988) Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J. Neurochem. 51, 1190-1196.
46. Hadjiconstantinou M. and Neff N. H. (1990) Differential recovery of dopamine synthetic enzymes following MPTP and the consequences of GM1 ganglioside treatment. Eur. J. Pharmacol. 181, 137-139.
47. Hadjiconstantinou M., Rossetti Z. L., Paxton R. C., and Neff N. H. (1986) Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP. Neuropharmacology 25, 1075-1077.
48. Hadjiconstantinou M., Mariani A. P., and Neff N. H. (1989a) GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study. Brain Res. 484, 297-303.
49. Hadjiconstantinou M., Weihmuller F. B., and Neff N. H. (1989b) Treatment with GMl ganglioside reverses dopamine D-2 receptor supersensitivity induced by the neurotoxin MPTP. Eur. J. Pharmacol. 168, 261-264.
50. Hadjiconstantinou M., Yates A. J., and Neff N. H. (1990) Hypoxiainduced neurotransmitter deficits in neonatal rats are partially corrected by exogenous GM1 ganglioside. J. Neurochem. 55, 864-869.
51. Hadjiconstantinou M., Karadsheh N. S., Rattan A. K., Tejwani G. A., Fitkin J. G., and Neff N. H. (1992) GM1 ganglioside enhances cholinergic parameters in the brain of senescent rats. Neuroscience 46, 681-686.
52. Hefti F., Hartikka J., and Frick W. (1985) Gangliosides alter morphology and growth of astrocytes and increase the activity of choline acetyltransferase in cultures of dissociated septal cells. J. Neurosci. 5, 2086-2094.
53. Herrero M. T., Kastner A., Perez-Otano I., Hirsch E. C., Luquin M. R., Javoy-Agid F., Del Rio J., Obeso J. A., and Agid Y. (1993a) Gangliosides and parkinsonism. Neurology 43, 2132-2134.
54. Herrero M. T., Perez-Otano I., Oset C., Kastner A., Hirsch E. C., Agid Y., Luquin M. R., Obeso J. A., and Del Rio J. (1993b) GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys. Neuroscience 56, 965-972.
55. Jackson E. A., Jenner P., and Marsden C. D. (1989) Behavioural and morphological changes following treatment with GM-1 ganglioside of rats with an electrolytic lesion of the substantia nigra. Neuropharmacology 28, 543-555.
56. Janson A. M., Agnati L. F., Fuxe K., Cintra A., Sundstrom E., Zini I., Toffano G., and Goldstein M. (1988) GM1 ganglioside protects against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol. Scand. 132, 587-588.
57. Johnson G. V., Simonato M., and Jope R. S. (1988) Dose-and time-dependent hippocampal cholinergic lesions induced by ethylcholine mustard aziridinium ion: effects of nerve growth factor, GM1 ganglioside, and vitamin E. Neurochem. Res. 13, 685-692.
58. Jonsson G., Gorio A., Hallman H., Janigro D., Kojima H., Luthman J., and Zanoni R. (1984a) Effects of GM1 ganglioside on developing and mature serotonin and noradrenaline neurons lesioned by selective neurotoxins. J. Neurosci. Res. 12, 459-475.
59. Jonsson G., Gorio A., Hallman H., Janigro D., Kojima H., and Zanoni R. (1984b) Effect of GM1 ganglioside on neonatally neurotoxin induced degeneration of serotonin neurons in the rat brain. Brain Res. 318, 171-180.
60. Jope R. S., Baker H. J., and Connor D. J. (1986) Increased acetylcholine synthesis and release in brains of cats with GM1 gangliosidosis. J. Neurochem. 46, 1567-1572.
61. Kharlamov A., Zivkovic I., Polo A., Armstrong D. M., Costa E., and Guidotti A. (1994) LIGA20, a lyso derivative of ganglioside GM1, given orally after cortical thrombosis reduces infarct size and associated cognition deficit. Proc. Natl. Acad. Sci. USA 91, 6303-6307.
62. Koga T., Kojima H., Yamada S., Miki K., Nishi S., Inanaga K., Shoji H., Kaji M., Jonsson G., and Toffano G. (1990) GM1 ganglioside reduces edema and monoaminergic neuronal changes following experimental focal ischemia in rat brain. Brain Res. 524, 313-315.
63. Kojima H., Gorio A., Janigro D., and Jonsson G. (1984) GM1 ganglioside enhances regrowth of noradrenaline nerve terminals in rat cerebral cortex lesioned by the neurotoxin 6-hydroxydopamine. Neuroscience 13, 1011-1022.
64. Kojima H., Yamada S., Yokoo H., Tsutsumi T., Nishi S., Inanaga K., Nagatsu I., Jonsson G., and Toffano G. (1988) The effects of exogenous GM1 ganglioside on neurotoxin induced damage of cerebral serotonin nerve terminals in adult rats. Kurume Med. J. 35, 49-61.
65. Krajnc D., Wemlinger T. A., Neff N. H., and Hadjiconstantinou M. (1994) Neonatal hypoxia: early neurotransmitter responses and the consequences of treatment with GM1 ganglioside. J. Pharmacol. Exp. Ther. 271, 1299-1305.
66. Leavitt B. R. and Maysinger D. ( 1991 ) Lesions of the nucleus basalis magnocellularis of rat by hemicholinium mustard: protection with monosialoganglioside GM1. Neurochem. Int. 19, 113-123.
67. Leon A., Dal Toso R., Presti D., Benvegnu D., Facci L., Kirschner G., Tettamanti G., and Toffano G. (1988) Development and survival of neurons in dissociated fetal mesencephalic serum-free cell cultures: II. Modulatory effects of gangliosides. J. Neurosci. 8, 746-753.
68. Liberini P., Pioro E. P., Maysinger D., Ervin F. R., and Cuello A. C. (1993) Long-term protective effects of human recombinant nerve growth factor and monosialoganglioside GM1 treatment on primate nucleus basalis cholinergic neurons after neocortical infarction. Neuroscience 53, 625-637.
69. Lidsky T. I., Schneider J. S., Zuck L. G., Yabolonsky-Alter E., and Banerjee S. P. (1994) GM1 ganglioside attenuates changes in neurochemistry and behavior caused by repeated haloperidol administration. Neurogeneration 3, 135-140.
70. Lombardi G., Beni M., Carlà V., Toffano G., and Moroni F. (1988a) Differential actions of neurotrophic factors on lesion-induced damage of the serotonergic neurons projecting to the hippocampus. Brain Res. 458, 348-352.
71. Lombardi G., Beni M., Consolazione A., and Moroni F. (1988b) Lesioning and recovery of the serotoninergic hippocampal afferents: differential effects of GM1 ganglioside. Neuropharmacology 27, 1085-1088.
72. Lombardi G., Zanoni R., and Moroni F. (1989) Systemic treatments with GM1 ganglioside reduce quinolinic acid-induced striatal lesions in the rat. Eur. J. Pharmacol. 174, 123-125.
73. Mahadik S. P., Vilim F., Korenovsky A., and Karpiak S. E. (1988) GM1 ganglioside protects nucleus basalis from excitotoxin damage: reduced cortical cholinergic losses and animal mortality. J. Neurosci. Res. 20, 479-483.
74. Manev H., Costa E., Wroblewski J. T., and Guidotti A. (1990) Abusive stimulation of excitatory amino acid receptors: a strategy to limit neurotoxicity. FASEB J. 4, 2789-2797.
75. Marlier L., Poulat P., Konig N., Drian M. J., and Privat A. (1989) Influence of GM1 gangliosides on the growth of cultured rat embryonic serotonergic neurons. Int. J. Dev. Neurosci. 7, 655-665.
76. Maysinger D., Herrera-Marschitz M., Ungerstedt U., and Cuello A. C. (1990a) Acetylcholine release in vivo: effects of chronic treatment with monosialoganglioside GM1. Neuropharmacology 29, 151-159.
77. Maysinger D., Herrera-Marschitz M., Ungerstedt U., and Cuello A. C. (1990b) Effects of treatment with microencapsulated monosialoganglioside GM1 on cortical and striatal acetylcholine release in rats with cortical devascularizing lesions. Neurosci. Lett. 118, 252-256.
78. Mutoh T., Tokuda A., Miyadai T., Hamaguchi M., and Fujiki N. (1995) Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc. Natl. Acad. Sci. USA 92, 5087-5091.
79. Orlando P., Cocciante G., Ippolito G., Massari P., Roberti S., and Tettamanti G. (1979) The fate of tritium labeled GM1 ganglioside injected in mice. Pharmacol. Res. Commun. 11, 759-773.
80. Pedata F., Giovannelli L., and Pepeu G. (1984) GM1 ganglioside facilitates the recovery of high-affinity choline uptake in the cerebral cortex of rats with a lesion of the nucleus basalis magnocellularis. J. Neurosci. Res. 12, 421-427.
81. NGFR-containing cholinergic neurons are protected from retrograde degeneration by the ganglioside GM1. Neuroscience 53, 49-56.
82. Polo A., Kirschner G., Guidotti A., and Costa E. (1994) Brain content of glycosphingolipids after oral administration of monosialogangliosides GM1 and LIGA20 to rats. Mol. Chem. Neuropathol. 21, 41-53.
83. Rabin S. J. and Mocchetti I. (1995) GM1 ganglioside activates the high-affinity nerve growth factor receptor trkA. J. Neurochem. 65, 347-354.
84. Raiteri M., Versace P., and Marchi M. (1985) GM1 monosialoganolioside inner ester induces early recovery of striatal dopamine uptake in rats with unilateral nigrostriatal lesion. Eur. J. Pharmacol. 118, 347-350.
85. Raiteri M., Versace P., Maura G., and Marchi M. (1988) Parenteral treatment with GM1 monosialoganglioside induces recovery of dopamine synthesis and release following nigrostriatal hemitransection. Neurosci. Res. Commun. 3, 69-75.
86. Ricaurte G. A., Irwin I., Forno L. S., Delanney L. E., Langston E., and Langston J. W. (1987) Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res. 403, 43-51.
87. Sabel B. A., Dunbar G. L., and Stein D. G. (1984) Gangliosides minimize behavioral deficits and enhance structural repair after brain injury. J. Neurosci. Res. 12, 429-443.
88. Saulino M. F. and Schengrund C. L. (1994) Differential accumulation of gangliosides by the brains of MPTP-lesioned mice. J. Neurosci. Res. 37, 384-391.
89. Schengrund C. L. (1990) The role(s) of gangliosides in neural differentiation and repair: a perspective. Brain Res. Bull. 24, 131-141.
90. Schneider J. S. (1994) The therapeutic role of gangliosides in neurological disorders. CNS Drugs 3, 213-222.
91. Schneider J. S. and DiStefano L. (1993) LIGA 20 increases striatal dopamine levels in aged MPTP-treated mice refractory to GM1 ganglioside treatment. Neuroreport 5, 103-104.
92. Schneider J. S. and DiStefano L. (1994) Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in murine model of parkinsonism. Neurology 44, 748-750.
93. Schneider J. S. and DiStefano L. (1995a) Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments. Brain Res. 674, 260-264.
94. Schneider J. S. and DiStefano L. (1995b) Response of damaged dopamine system to GM1 and semi synthetic gangliosides: effects of dose and extent of lesion. Neuropharmacology 34, 489-493.
95. Schneider J. S. and Yuwiler A. (1989) GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism. Exp. Neurol. 105, 177-183.
96. Schneider J. S., Pope A., Simpson K., Taggart J., Smith M. G., and DiStefano L. (1992) Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 256, 843-846.
97. Schneider J. S., Kean A., and DiStefano L. (1995) GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. J. Neurosci. Res. 42, 117-123.
98. Shieemori M., Okamoto Y., Watanabe T., and Kuramoto S. (1990) Effect of monosialoganglioside (GM1) on transected monoaminergic pathways. J. Neurotrauma 7, 89-97.
99. Silva R. H., Felicio L. F., Nasello A. G., Vital M. A. B. F., and Frussa-Filho R. (1996) Effect of ganglioside (GM1) on memory in senescent rats. Neurobiol. Aging 17, 583-586.
100. Skaper S. D., Facci L., Schiavo N., Vantini G., Moroni F., Dal Toso R., and Leon A. (1992) Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1 : implications for Parkinson's disease. J. Pharmacol. Exp. Ther. 263, 1440-1446.
101. Skaper S. D., Fadda E., Facci L., and Manev H. (1993) A semisynthetic glycosphingolipid (LIGA20) reduces 2,4,5-trihydroxyphenylalanine neurotoxicity in primary neuronal cultures. Eur. J. Pharmacol. 243, 91-93.
102. Sofroniew M. V., Pearson R. C., Cuello A. C., Tagari P. C., and Stephens P. H. (1986) Parenterally administered GM1 ganglioside prevents retrograde degeneration of cholinergic cells of the rat basal forebrain. Brain Res. 398, 393-396.
103. Stephens P. H., Tagari P. C., Garofalo L., Maysinger D., Piotte M., and Cuello A. C. (1987) Neural plasticity of basal forebrain cholinergic neurons: effects of gangliosides. Neurosci. Lett. 80, 80-84.
104. Stephens P. H., Tagari P. C., and Cuello A. C. (1988) Retrograde degeneration of basal forebrain cholinergic neurons after neurotoxin lesions of the neocortex: application of ganglioside GM1. Neurochem. Int. 12, 475-481.
105. Stull N. D., Schneider J. S., and Iacovitti L. (1994) GM1 ganglioside partially rescues cultured dopaminergic neurons from MPP(+)-induced damage: dependence on initial damage and time of treatment. Brain Res. 640, 308-315.
106. Tettamanti G. and Ribona L. (1993) Gangliosides and modulation of the function of neural cells. Adv. Lipid Res. 25, 235-267.
107. Tettamanti G., Venerando B., Roberti S., Chigorno V., Sonnino S., Ghidoni R., Orlando P., and Massari P. (1981) The fate of exogenously administered brain gangliosides, in Gangliosides in Neurological and Neuromuscular Function, Development, and Repair (Rapport M. M. and Gorio A., eds), pp. 225-240. Raven Press, New York.
108. Tilson H. A., Harry G. J., Nanry K., Hudson P. M., and Hong J. S. (1988) Ganglioside interactions with the dopaminergic system of rats. J. Neurosci. Res. 19, 88-93.
109. Toffano G., Savoini G., Moroni F., Lombardi G., Calza L., and Agnati L. F. (1983) GM1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system. Brain Res. 261, 163-166.
110. Toffano G., Agnati L. F., Fuxe K., Aldinio C., Consolazione A., Valenti G., and Savoini G. (1984a) Effect of GM1 ganglioside treatment on the recovery of dopaminergic nigrostriatal neurons after different types of lesion. Acta Physiol. Scand. 122, 313-321.
111. Toffano G., Savoini G. E., Moroni F., Lombardi G., Calza L., and Agnati L. F. (1984b) Chronic GM1 ganglioside treatment reduces dopamine cell body degeneration in the substantia nigra after unilateral hemitransection in rat. Brain Res. 296, 233-239.
112. Vogelsberg V., Fong T. G., Neff N. H., and Hadjiconstantinou M. (1997) Cholinergic deficits in aged rat spinal cord: restoration by GM1 ganglioside. Brain Res. 761, 250-256.
113. Weihmuller F. B., Hadjiconstantinou M., and Bruno J. P. (1988a) Acute stress or neuroleptics elicit sensorimotor deficits in MPTP-treated mice. Neurosci. Lett. 85, 137-142.
114. Weihmuller F. B., Hadjiconstantinou M., Bruno J. P., and Neff N. H. (1988b) Administration of GM1 ganglioside eliminates neuroleptic-induced sensorimotor deficits in MPTP-treated mice. Neurosci. Lett. 92, 207-212.
115. Weihmuller F. B., Hadjiconstantinou M., Bruno J. P., and Neft N. H. (1989) Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice. Life Sci. 45, 2495-2502.
116. Wells J. M., Ventura R. F., Eisenhauer P. B., McKenna D. C., Fine R. E., and Ullman M. D. (1996) Transport of GM1 and GM1 inner ester across an in vitro model of the blood-brain barrier. Neurosci. Lett. 217, 121-124.
117. Whittaker V. P., Derrington E. A., and Borroni E. (1992) Chol-1 is a cholinergic marker in the human central nervous system. Neuroreport 3, 341-344.
118. Wojcik M., Ulas J., and Oderfeld-Nowak B. (1982) The stimulating effect of ganglioside injections on the recovery of the choline acetyltransferase and the acetylcholinesterase activities in the hippocampus of the rat after septal lesions. Neuroscience 7, 495-499.
119. Zeller C. B. and Marchase R. B. (1992) Gangliosides as modulators of cell function. Am. J. Physiol. 262, C1341-C1355.